The Peripheral Neuropathy Evaluation in an Office-Based Neurology Setting

Michael W Vavra; Devon I Rubin

doi:10.1055/s-0031-1271305

Seminars in Neurology, Table of Contents

Semin Neurol 2011; 31(1): 102-114
DOI: 10.1055/s-0031-1271305

The Peripheral Neuropathy Evaluation in an Office-Based Neurology Setting

Michael W. Vavra¹ , Devon I. Rubin²

¹Tri-State Mountain Neurology Associates, Johnson City, Tennessee
²Department of Neurology, Mayo Clinic, Jacksonville, Florida

Abstract

ABSTRACT

Peripheral neuropathy is the most common neuromuscular disorder encountered in a neurologic practice. The evaluation of patients with suspected peripheral neuropathy can be a challenging endeavor for the neurologist. Determining the pattern of clinical involvement and the nerve modalities affected can help to generate a differential diagnosis and design an approach to determine a potential cause. The combination of clinical features, electrodiagnostic testing, and ancillary laboratory studies may be used to determine the etiology. As the most common acquired etiology of peripheral neuropathy is diabetes, careful testing for impaired glucose metabolism is an important part of any diagnostic evaluation.

KEYWORDS

Neuropathy

Full Text

References

REFERENCES

1 England J D, Asbury A K. Peripheral neuropathy. Lancet. 2004; 363 (9427) 2151-2161
2 Fagius J. Chronic cryptogenic polyneuropathy. The search for a cause. Acta Neurol Scand. 1983; 67 (3) 173-180
3 Prineas J. Polyneuropathies of undetermined cause. Acta Neurol Scand Suppl. 1970; 44 1-72
4 Smith A G, Singleton J R. The diagnostic yield of a standardized approach to idiopathic sensory-predominant neuropathy. Arch Intern Med. 2004; 164 (9) 1021-1025
5 Dyck P J, Oviatt K F, Lambert E H. Intensive evaluation of referred unclassified neuropathies yields improved diagnosis. Ann Neurol. 1981; 10 (3) 222-226
6 Barohn R J. Approach to peripheral neuropathy and neuronopathy. Semin Neurol. 1998; 18 (1) 7-18
7 Research criteria for diagnosis of chronic inflammatory demyelinating polyneuropathy (CIDP). Report from an Ad Hoc Subcommittee of the American Academy of Neurology AIDS Task Force. Neurology. 1991; 41 (5) 617-618
8 Joint Task Force of the EFNS and the PNS . European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy. Report of a Joint Task Force of the European Federation of Neurological Societies and the Peripheral Nerve Society. J Peripher Nerv Syst. 2005; 10 (3) 220-228
9 Haq R U, Fries T J, Pendlebury W W, Kenny M J, Badger G J, Tandan R. Chronic inflammatory demyelinating polyradiculoneuropathy: a study of proposed electrodiagnostic and histologic criteria. Arch Neurol. 2000; 57 (12) 1745-1750
10 Hughes R, Bensa S, Willison H Inflammatory Neuropathy Cause and Treatment (INCAT) Group et al. Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol. 2001; 50 (2) 195-201
11 Nicolas G, Maisonobe T, Le Forestier N, Léger J M, Bouche P. Proposed revised electrophysiological criteria for chronic inflammatory demyelinating polyradiculoneuropathy. Muscle Nerve. 2002; 25 (1) 26-30
12 Thaisetthawatkul P, Logigian E L, Herrmann D N. Dispersion of the distal compound muscle action potential as a diagnostic criterion for chronic inflammatory demyelinating polyneuropathy. Neurology. 2002; 59 (10) 1526-1532
13 Bromberg M B. Comparison of electrodiagnostic criteria for primary demyelination in chronic polyneuropathy. Muscle Nerve. 1991; 14 (10) 968-976
14 Magda P, Latov N, Brannagan III T H, Weimer L H, Chin R L, Sander H W. Comparison of electrodiagnostic abnormalities and criteria in a cohort of patients with chronic inflammatory demyelinating polyneuropathy. Arch Neurol. 2003; 60 (12) 1755-1759
15 Molenaar D S, Vermeulen M, de Haan R J. Comparison of electrodiagnostic criteria for demyelination in patients with chronic inflammatory demyelinating polyneuropathy (CIDP). J Neurol. 2002; 249 (4) 400-403
16 Van den Bergh P Y, Piéret F. Electrodiagnostic criteria for acute and chronic inflammatory demyelinating polyradiculoneuropathy. Muscle Nerve. 2004; 29 (4) 565-574
17 Jann S, Beretta S, Bramerio M, Defanti C A. Prospective follow-up study of chronic polyneuropathy of undetermined cause. Muscle Nerve. 2001; 24 (9) 1197-1201
18 Lubec D, Müllbacher W, Finsterer J, Mamoli B. Diagnostic work-up in peripheral neuropathy: an analysis of 171 cases. Postgrad Med J. 1999; 75 (890) 723-727
19 Wolfe G I, Baker N S, Amato A A et al.. Chronic cryptogenic sensory polyneuropathy: clinical and laboratory characteristics. Arch Neurol. 1999; 56 (5) 540-547
20 Notermans N C, Wokke J H, Franssen H et al.. Chronic idiopathic polyneuropathy presenting in middle or old age: a clinical and electrophysiological study of 75 patients. J Neurol Neurosurg Psychiatry. 1993; 56 (10) 1066-1071
21 Notermans N C, Wokke J H, van der Graaf Y, Franssen H, van Dijk G W, Jennekens F G. Chronic idiopathic axonal polyneuropathy: a five year follow up. J Neurol Neurosurg Psychiatry. 1994; 57 (12) 1525-1527
22 McLeod J G, Tuck R R, Pollard J D, Cameron J, Walsh J C. Chronic polyneuropathy of undetermined cause. J Neurol Neurosurg Psychiatry. 1984; 47 (5) 530-535
23 Johannsen L, Smith T, Havsager A M et al.. Evaluation of patients with symptoms suggestive of chronic polyneuropathy. J Clin Neuromuscul Dis. 2001; 3 (2) 47-52
24 Saperstein D S, Wolfe G I, Gronseth G S et al.. Challenges in the identification of cobalamin-deficiency polyneuropathy. Arch Neurol. 2003; 60 (9) 1296-1301
25 Bednarik J, Vlckova-Moravcova E, Bursova S, Belobradkova J, Dusek L, Sommer C. Etiology of small-fiber neuropathy. J Peripher Nerv Syst. 2009; 14 (3) 177-183
26 Sorenson E J, Windebank A J. Hypertriglyceridemia in idiopathic painful small fiber neuropathy. Neurology. 2000; 54 (Suppl 3) A403
27 Singleton J R, Smith A G, Bromberg M B. Increased prevalence of impaired glucose tolerance in patients with painful sensory neuropathy. Diabetes Care. 2001; 24 (8) 1448-1453
28 Hoffman-Snyder C, Smith B E, Ross M A, Hernandez J, Bosch E P. Value of the oral glucose tolerance test in the evaluation of chronic idiopathic axonal polyneuropathy. Arch Neurol. 2006; 63 (8) 1075-1079
29 Centers for Disease Control and Prevention (CDC) . Prevalence of diabetes and impaired fasting glucose in adults—United States, 1999-2000. MMWR Morb Mortal Wkly Rep. 2003; 52 (35) 833-837
30 Novella S P, Inzucchi S E, Goldstein J M. The frequency of undiagnosed diabetes and impaired glucose tolerance in patients with idiopathic sensory neuropathy. Muscle Nerve. 2001; 24 (9) 1229-1231
31 Gabriel C M, Howard R, Kinsella N et al.. Prospective study of the usefulness of sural nerve biopsy. J Neurol Neurosurg Psychiatry. 2000; 69 (4) 442-446
32 England J D, Gronseth G S, Franklin G American Academy of Neurology et al. Practice Parameter: evaluation of distal symmetric polyneuropathy: role of autonomic testing, nerve biopsy, and skin biopsy (an evidence-based review). Report of the American Academy of Neurology, American Association of Neuromuscular and Electrodiagnostic Medicine, and American Academy of Physical Medicine and Rehabilitation. Neurology. 2009; 72 (2) 177-184
33 Hlubocky A, Wellik K, Ross M A et al.. Skin biopsy for diagnosis of small fiber neuropathy: a critically appraised topic. Neurologist. 2010; 16 (1) 61-63
34 Koskinen M, Hietaharju A, Kyläniemi M et al.. A quantitative method for the assessment of intraepidermal nerve fibers in small-fiber neuropathy. J Neurol. 2005; 252 (7) 789-794
35 Løseth S, Lindal S, Stålberg E, Mellgren S I. Intraepidermal nerve fibre density, quantitative sensory testing and nerve conduction studies in a patient material with symptoms and signs of sensory polyneuropathy. Eur J Neurol. 2006; 13 (2) 105-111
36 Shun C T, Chang Y C, Wu H P et al.. Skin denervation in type 2 diabetes: correlations with diabetic duration and functional impairments. Brain. 2004; 127 (Pt 7) 1593-1605
37 Sinnreich M, Taylor B V, Dyck P J. Diabetic neuropathies. Classification, clinical features, and pathophysiological basis. Neurologist. 2005; 11 (2) 63-79
38 Dyck P J, Kratz K M, Karnes J L et al.. The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort: the Rochester Diabetic Neuropathy Study. Neurology. 1993; 43 (4) 817-824
39 Dyck P J, Giannini C. Pathologic alterations in the diabetic neuropathies of humans: a review. J Neuropathol Exp Neurol. 1996; 55 (12) 1181-1193
40 The Diabetes Control and Complications Trial Research Group . The effect of intensive diabetes therapy on the development and progression of neuropathy. Ann Intern Med. 1995; 122 (8) 561-568
41 Kelly Jr J J, Kyle R A, O'Brien P C, Dyck P J. Prevalence of monoclonal protein in peripheral neuropathy. Neurology. 1981; 31 (11) 1480-1483
42 Latov N, Braun P E, Gross R B, Sherman W H, Penn A S, Chess L. Plasma cell dyscrasia and peripheral neuropathy: identification of the myelin antigens that react with human paraproteins. Proc Natl Acad Sci U S A. 1981; 78 (11) 7139-7142
43 Latov N, Hays A P, Sherman W H. Peripheral neuropathy and anti-MAG antibodies. Crit Rev Neurobiol. 1988; 3 (4) 301-332
44 Comi G, Roveri L, Swan A Inflammatory Neuropathy Cause and Treatment Group et al. A randomised controlled trial of intravenous immunoglobulin in IgM paraprotein associated demyelinating neuropathy. J Neurol. 2002; 249 (10) 1370-1377
45 Dalakas M C, Quarles R H, Farrer R G et al.. A controlled study of intravenous immunoglobulin in demyelinating neuropathy with IgM gammopathy. Ann Neurol. 1996; 40 (5) 792-795
46 Dyck P J, Low P A, Windebank A J et al.. Plasma exchange in polyneuropathy associated with monoclonal gammopathy of undetermined significance. N Engl J Med. 1991; 325 (21) 1482-1486
47 Ernerudh J H, Vrethem M, Andersen O, Lindberg C, Berlin G. Immunochemical and clinical effects of immunosuppressive treatment in monoclonal IgM neuropathy. J Neurol Neurosurg Psychiatry. 1992; 55 (10) 930-934
48 Mariette X, Chastang C, Clavelou P, Louboutin J P, Leger J M, Brouet J C. A randomised clinical trial comparing interferon-alpha and intravenous immunoglobulin in polyneuropathy associated with monoclonal IgM. The IgM-associated Polyneuropathy Study Group. J Neurol Neurosurg Psychiatry. 1997; 63 (1) 28-34
49 Nobile-Orazio E, Baldini L, Barbieri S et al.. Treatment of patients with neuropathy and anti-MAG IgM M-proteins. Ann Neurol. 1988; 24 (1) 93-97
50 Nobile-Orazio E, Meucci N, Baldini L, Di Troia A, Scarlato G. Long-term prognosis of neuropathy associated with anti-MAG IgM M-proteins and its relationship to immune therapies. Brain. 2000; 123 (Pt 4) 710-717
51 Lewis R A. Chronic inflammatory demyelinating polyneuropathy. Neurol Clin. 2007; 25 (1) 71-87
52 Ruts L, Drenthen J, Jacobs B C, van Doorn P A. Dutch GBS Study Group . Distinguishing acute-onset CIDP from fluctuating Guillain-Barre syndrome: a prospective study. Neurology. 2010; 74 (21) 1680-1686
53 Hahn A F, Bolton C F, Zochodne D, Feasby T E. Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy. A double-blind, placebo-controlled, cross-over study. Brain. 1996; 119 (Pt 4) 1067-1077
54 Dyck P J, Litchy W J, Kratz K M et al.. A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol. 1994; 36 (6) 838-845
55 Katz U, Achiron A, Sherer Y, Shoenfeld Y. Safety of intravenous immunoglobulin (IVIG) therapy. Autoimmun Rev. 2007; 6 (4) 257-259
56 Brannagan III T H. Intravenous gammaglobulin (IVIg) for treatment of CIDP and related immune-mediated neuropathies. Neurology. 2002; 59 (12, Suppl 6) S33-S40
57 Klein C J. The inherited neuropathies. Neurol Clin. 2007; 25 (1) 173-207
58 Benson M D, Kincaid J C. The molecular biology and clinical features of amyloid neuropathy. Muscle Nerve. 2007; 36 (4) 411-423
59 Wierzbicki A S, Lloyd M D, Schofield C J, Feher M D, Gibberd F B. Refsum's disease: a peroxisomal disorder affecting phytanic acid alpha-oxidation. J Neurochem. 2002; 80 (5) 727-735
60 Pollock M, Nukada H, Frith R W, Simcock J P, Allpress S. Peripheral neuropathy in Tangier disease. Brain. 1983; 106 (Pt 4) 911-928
61 Schiffmann R. Fabry disease. Pharmacol Ther. 2009; 122 (1) 65-77
62 Albers J W, Fink J K. Porphyric neuropathy. Muscle Nerve. 2004; 30 (4) 410-422
63 Hansen L M, Kristensen O, Friis M L. [Neuropathy in adult metachromatic leukodystrophy]. Ugeskr Laeger. 1994; 156 (15) 2252-2253
64 Marks H G, Scavina M T, Kolodny E H, Palmieri M, Childs J. Krabbe's disease presenting as a peripheral neuropathy. Muscle Nerve. 1997; 20 (8) 1024-1028
65 van Geel B M, Assies J, Wanders R J, Barth P G. X linked adrenoleukodystrophy: clinical presentation, diagnosis, and therapy. J Neurol Neurosurg Psychiatry. 1997; 63 (1) 4-14
66 Walker R H, Jung H H, Dobson-Stone C et al.. Neurologic phenotypes associated with acanthocytosis. Neurology. 2007; 68 (2) 92-98
67 Di Donato S. Multisystem manifestations of mitochondrial disorders. J Neurol. 2009; 256 (5) 693-710
68 Bennett C L, Lawson V H, Brickell K L et al.. Late-onset hereditary axonal neuropathies. Neurology. 2008; 71 (1) 14-20
69 England J D, Gronseth G S, Franklin G American Academy of Neurology et al. Practice parameter: the evaluation of distal symmetric polyneuropathy: the role of laboratory and genetic testing (an evidence-based review). Report of the American Academy of Neurology, the American Association of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation. PM R. 2009; 1 (1) 5-13
70 Goldstein D J, Lu Y, Detke M J, Lee T C, Iyengar S. Duloxetine vs. placebo in patients with painful diabetic neuropathy. Pain. 2005; 116 (1-2) 109-118
71 Raskin J, Pritchett Y L, Wang F et al.. A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain. Pain Med. 2005; 6 (5) 346-356
72 Lesser H, Sharma U, LaMoreaux L, Poole R M. Pregabalin relieves symptoms of painful diabetic neuropathy: a randomized controlled trial. Neurology. 2004; 63 (11) 2104-2110
73 Richter R W, Portenoy R, Sharma U, Lamoreaux L, Bockbrader H, Knapp L E. Relief of painful diabetic peripheral neuropathy with pregabalin: a randomized, placebo-controlled trial. J Pain. 2005; 6 (4) 253-260
74 Rosenstock J, Tuchman M, LaMoreaux L, Sharma U. Pregabalin for the treatment of painful diabetic peripheral neuropathy: a double-blind, placebo-controlled trial. Pain. 2004; 110 (3) 628-638

Devon I RubinM.D.

Department of Neurology, Mayo Clinic

4500 San Pablo Road, Jacksonville, FL 32224

Email: Rubin.Devon@mayo.edu